High-Dose Cyclophosphamide for Steroid Refractory GVHD
Status:
Completed
Trial end date:
2013-01-01
Target enrollment:
Participant gender:
Summary
RATIONALE: High-dose cyclophosphamide may be an effective treatment for acute
graft-versus-host disease that did not respond to steroid therapy.
PURPOSE: This phase II trial is studying the side effects, best dose, and how well high-dose
cyclophosphamide works in treating patients with acute graft-versus-host disease that did not
respond to steroid therapy.
Phase:
Phase 2
Details
Lead Sponsor:
Sidney Kimmel Comprehensive Cancer Center Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins